Stocktoria
Serina Therapeutics, Inc. SER
Serina Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-30. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | 3.2% | 61.8% | 86.8% | 92.8% | 85.9% | 73.9% | 88.0% |
| Operating margin | -18478.5% | -30442.9% | -99.2% | -20514.7% | -5509.0% | -2797.8% | -726.8% | -805.5% | -474.6% |
| Net margin | -14755.4% | -19894.6% | 167.1% | -30770.6% | -6024.3% | -3009.7% | -703.4% | -537.4% | -468.7% |
| FCF margin | -13856.9% | -30641.1% | — | — | — | -2223.8% | -625.1% | -574.2% | -447.7% |
| Return on assets | -276.0% | -165.7% | 58.8% | -322.8% | -275.0% | -276.8% | -163.3% | -70.3% | -68.3% |
| Return on equity | 51843.2% | -1738.1% | -16.3% | 27.7% | 73.1% | 201.4% | -464.4% | -91.1% | -79.1% |
| Debt / equity | — | — | — | -0.48× | -1.11× | — | — | — | — |
| Current ratio | 1.71 | 2.40 | 5.39 | 0.24 | 0.25 | 0.43 | 1.23 | 3.22 | — |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.